Search

Subodh Verma

Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19)
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study

Published with Wowchemy — the free, open source website builder that empowers creators.